Introduction: Infarction-related cardiogenic shock (ICS) is usually due to leftventricular pump failure. With a mortality of 30% to 80%, ICS is the most common cause of death from acute myocardial infarction. The S3 guideline presented here characterizes the current evidence-based treatment of ICS: early revascularization, treatment of shock, and intensive care treatment of multi-organ dysfunction syndrome (MODS) if it arises. The success or failure of treatment for MODS determines the outcome in ICS.
Methods: Experts from eight German and Austrian specialty societies analyzed approximately 3600 publications that had been retrieved by a systematic literature search. Three interdisciplinary consensus conferences were held, resulting in the issuing of 111 recommendations and algorithms for this S3 guideline.
Results: Early revascularization of the occluded vessel, usually with a percutaneous coronary intervention (PCI), is of paramount importance. The medical treatment of shock consists of dobutamine as the inotropic agent and norepinephrine as the vasopressor of choice and is guided by a combination of pressure and flow values, or by the cardiac power index. Levosimendan can be given in addition to treat catecholamine-resistant shock. For patients with ICS who are treated with PCI, the current S3 guideline differs from the European and American myocardial infarction guidelines with respect to the recommendation for intra-aortic balloon pulsation (IABP): Whereas the former guidelines give a class I recommendation for IABP, this S3 guideline states only that IABP "can" be used in this situation, in view of the poor state of the evidence. Only for patients being treated with systemic fibrinolysis is IABP weakly recommended (IABP "should" be used in such cases). With regard to the optimal intensive-care interventions for the prevention and treatment of MODS, recommendations are given concerning ventilation, nutrition, erythrocyte-concentrate transfusion, prevention of thrombosis and stress ulcers, follow-up care, and rehabilitation.
Discussion: The goal of this S3 guideline is to bring together the types of treatment for ICS that lie in the disciplines of cardiology and intensive-care medicine, as patients with ICS die not only of pump failure, but also (and even more frequently) of MODS. This is the first guideline that adequately emphasizes the significance of MODS as a determinant of the outcome of ICS. ►Cite this as:
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A German-Austrian S3 guideline. Dtsch Arztebl Int 2012; 109 (19) : 343-51. DOI: 10.3238/arztebl.2012.0343 P rovided they reach hospital, patients with acute myocardial infarction have a more than 90% probability of surviving (1) . If cardiogenic shock develops, however, whether initially or in the course of the infarction, only one in two survives (2) . All the progress made in the treatment of myocardial infarction seems to have ground to a halt before these 5% to 10% of heart attack patients: The publication of the most important evidence-based progress in treatment of patients with infarction-related cardiogenic shock (ICS)-the earliest possible reperfusion of the infarcted vessel by percutaneous coronary intervention (PCI)-is already more than 10 years old (3) .
One main cause of the high mortality among patients with ICS is the development of prolonged shock leading to multiorgan dysfunction syndrome (MODS) (4) . Consequently, ICS is not just a disease of the heart, but a disease of all the organs of the patient, who requires intensive care.
The current European (5) and American myocardial infarction guidelines focus their recommendations on "cardiological" treatment of the coronary arteries and the cardiovascular system; the "intensive care medicine" treatment of MODS is little regarded. This deficit motivated German and Austrian cardiologists, intensivists, cardiac surgeons, anesthetists, and rehabilitation specialists, together with their professional associations, to develop an S3 guideline for "infarctionrelated cardiogenic shock", under the auspices of the Association of Scientific Medical Societies in Germany (AWMF, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften). The aim of this German-Austrian guideline, with its seven algorithms and 111 recommendations, is to provide an adequate picture of both the cardiological and the intensive care aspects of this syndrome, since the prognosis of patients with ICS depends not only on the impaired cardiac function, but, much more, on the resulting impairment of organ blood supply and microcirculation with consequent MODS.
The full version and the guideline report are available at www.leitlinien.net (in German).
Shortened print versions have so far appeared in the journals Intensivmedizin und Notfallmedizin, Intensivund Notfallbehandlung, and Kardiologe (6).
BOX 1
• Deutsche Gesellschaft für Kardiologie -Herz und Kreislaufforschung (DGK) (German Cardiac Society) (lead society) (1) • Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN) (German Society of Intensive Care and Emergency Medicine) (2) • Deutsche Gesellschaft für Thorax-, Herz-und Gefäßchirurgie (DGTHG) (German Society for Thoracic and Cardiovascular Surgery) (3) • Österreichische Gesellschaft für Internistische und Allgemeine Intensivmedizin (ÖGIAIM) (Austrian Society of Internal and General Intensive Care Medicine) (4) • Deutsche Interdisziplinäre Vereinigung für Intensivmedizin (DIVI) (German Interdisciplinary Association of Intensive Care and Emergency Medicine) (5) • Österreichische Kardiologische Gesellschaft (ÖKG) (Austrian Society of Cardiology) (6) • Deutsche Gesellschaft für Anästhesie und Intensivmedizin (DGAI) (German Society of Anaesthesiology and Intensive Care Medicine) (7) • Deutsche Gesellschaft für Prävention und Rehabilitation (DGPR) Numbers in parentheses identify affiliation with a medical society. * Delegate of the relevant society with a vote in the nominal group process. Addresses are those valid at the time the guideline was being developed. (Table 1) . Before publication, the draft guideline was made available to other medical societies from October to December 2009 on the home page of the AWMF, the German Cardiac Society (Deutsche Gesellschaft für Kardiologie -Herzund Kreislaufforschung), and other medical societies for discussion (consultation phase). Comments were forwarded to the expert groups for their opinion and discussion as to whether any changes were needed (see Leitlinienreport at www.leitlinien.net). In the event no changes were made, but important comments were added as footnotes. All members agreed that there would be no patient participation (see Leitlinienreport at www.leitlinien.net).
Medical societies and experts involved in guideline development

Methods
Concept and development of the guideline
The guideline is valid until next revised or until January 2014 at the latest. The S3 guideline "Infarktbedingter kardiogener Schock: Diagnose, Monitoring und Therapie" (Infarction-Related Cardiogenic Shock: Diagnosis, Monitoring, and Treatment) was developed under conditions of editorial independence; coordination and logistic support were financed by the German Cardiac Society. Travel costs were borne by the medical societies, and the expert work was done on a voluntary basis without the payment of any fees. All the members of the guideline development group have declared any conflicts of interest relating to the development of the S3 guideline; the list forms part of the guideline report at www.leitli nien.net/.
The aims of the guideline and who the guideline is for
The aim of the S3 guideline "Infarktbedingter kardiogener Schock: Diagnose, Monitoring und Therapie" (Infarction-Related Cardiogenic Shock: Diagnosis, Monitoring, and Treatment) is to improve the quality of care of patients with ICS, by publishing evidence-based recommendations. It also presents the "state of the art" in diagnostics, monitoring, and treatment, thus representing a starting point for comparative studies. This is particularly to be emphasized, because many of the recommendations in this S3 guideline are based on expert opinions because of the lack of high-quality evidence.
The recommendations in the S3 guideline are directed at physicians managing patients with shock and acute myocardial infarction: that is, in particular, cardiologists and specialists in internal medicine, intensivists, heart surgeons, anesthetists, physicians working 
Recommendation grade and evidence levels
In accordance with the AWMF recommendation for recommendation grading, the recommendation and grading system of this S3 guideline follows the pattern of the National Care Guideline "Chronic CHD" (www. No recommendation: "may" (no confirmed study results exist that demonstrate either a beneficial or a harmful effect)
Rejected: "should not" (negative recommendation) Strongly rejected: "shall not" (strong negative recommendation)
High-quality systematic reviews of randomized controlled trials (RCTs) or RCTs with a very low risk of bias
Well performed systematic reviews of RCTs or RCTs with a low risk of bias High-quality systematic reviews of case-control or cohort studies with very low risk of confounders or bias and a high probability of causal relationships
Well performed systematic reviews of case-control or cohort studies with a low risk of confounders or bias and a moderate risk of noncausal relationships
Nonanalytic studies
Consensus opinion of experts based on studies and clinical experience or in the interests of patients' safety (e.g., monitoring)
BOX 2
Contents of the German-Austrian S3 guideline "Infarction-related cardiogenic shock: diagnosis, monitoring, and treatment"
Diagnosis, monitoring, and treatment of infarction-related cardiogenic shock Data acquisition and evaluation of recommendations and evidence A systematic search was conducted of international guidelines in order to produce a statement of the thematic areas and questions on which there was consensus ("source guidelines"; see Leitlinienreport at www. leitlinien.net/). In addition, a primary systematic literature search was carried out (PubMed: search terms (abstracts) "myocardial infarction and cardiogenic shock") ( Figure 3 ) of publications from 1 January 1990 to 30 September 2009 (3546 results). Evidence tables were produced for the themes "Revascularization" and "IABP implantation."
The evidence in the study data and the assigning of recommendation grades was done in the abovementioned nominal group process in accordance with the recommendation grades and evidence levels listed in Table 1 .
Results
The contents list of the guideline is reproduced in Box 2; a selection of the recommendations is given in eTable 1. Recommendations that particularly deserve discussion will be presented in more detail in the present article (Box 3).
Diagnosis and monitoring: initial phase
A preliminary diagnosis of "infarction-related cardiogenic shock" (ICS) (E 1/2 in eTable 1) usually has to be made quickly by the emergency physician during the prehospital phase on the basis of the 12-lead ECG ("STEMI," ST-segment elevation myocardial infarction) and clinical findings ("cardiogenic shock") (recommendation ↑↑). Even in the rare case of ICS following NSTEMI (no ST elevation on the ECG), the physician can diagnose ICS on the basis of clinical criteria in a patient with ACS.
The most important-though not ubiquitous-symptom of ICS is hypotension <90 mm Hg systolic for at least 30 minutes, associated with signs of reduced organ perfusion. Invasive measurement of cardiac output (e.g., cardiac index < 2.2 L × min -1 × m -2 and PAOP > 15 mm Hg) (3) is not necessary for a diagnosis of ICS. However, one patient in four with ICS presents without initial hypotension; in such cases, the diagnosis must rest on clinical signs of reduced organ perfusion (cold extremities, oliguria, altered mental status, e.g., agitation).
Revascularization
Revascularization of the infarcted coronary artery (Figure 1) Revascularization is the most important element of treatment of ICS. *1 After initial stabilization/before cardiac catheter investigation; *2 Persistent shock after revascularization; *3 Currently there is not enough evidence for the use of IABP in PCI or ACB; in patients who have received fibrinolytic treatment, the IABP should be used right ventricular infarction-is necessary so that the coronary intervention may be carried out safely and efficiently. The superiority of the principle of earliest possible coronary revascularization has been evident since the SHOCK trial (3, 7) . Early reperfusion of the coronary arteries is an important predictor of long-term survival (2) (eTable 2); when this is achieved, 132 lives can be saved for every 1000 shock patients treated (7) .
PCI on the coronary infarct artery usually takes the form of stent implantation (↑, E 14 in eTable 1) with intensive use of platelet aggregation inhibitors. If interventional revascularization is unsuccessful, surgery should be carried out as rapidly as possible. If several significant coronary stenoses are present, decisions may in some cases have to be made about further interventional or surgical revascularization.
Resuscitated patients form a special subgroup, which may make up as much as 30% of all patients with ICS (8, 9) . Early PCI should be considered in rapidly defibrillated patients (↑, E 78 in eTable 1) and mild hypothermia (32° to 34°C) induced for 12 to 24 hours (↑, E 79/80 in eTable 1).
Persistent shock after revascularization
The goals of hemodynamic management if shock symptoms persist are blood pressure stabilization and ensuring adequate organ perfusion (↑, E 32/33 in eTable 1; Figure 2 ). To achieve this goal with adequate preloading and the least possible use of catecholamines, close invasive monitoring including repetitive invasive measurement of cardiac output (↑↑, E 12) is necessary ( Figure 2 ). As to perfusion pressure, a mean arterial pressure between 65 and 75 mm Hg and cardiac index (cardiac output related to body surface area) of >2.5 L × min -1 × m -2 should be aimed at; as blood flow equivalents, a SVR of 800 to 1000 dyn × s × cm -5 , a S v O 2 >65%, or the cardiac power (product of cardiac output and mean arterial pressure as a measure of overall cardiac hydraulic performance) or cardiac power index (CP > 0.6 W or CPI > 0.4 W × m -2 ) (10-13) may be chosen instead of cardiac index (Figure 2) .
Which vasopressor and which inotrope?
Norepinephrine is the vasopressor of choice in patients with MAP values below 65 mm Hg (↑, Figure 2 ; E 34 to E 38 in eTable 1). The MAP can usually be effectively raised by intravenous infusion of 0.1 to 1 μg × kg -1 × min -1 . In the SOAP II study of 1679 patients with shock of various etiologies (14) , norepinephrine showed a tendency to lower mortality than dopamine (28-day mortality 45.9% vs. 50.2%; odds ratio [OR] 1.19; confidence interval [CI] 0.98 to 1.44; p = 0.07) and significantly fewer arrhythmias (12.4% vs. 24.1%), especially atrial fibrillation. In the prospectively defined subgroup of patients with cardiogenic shock, the norepinephrine treatment led to a significantly better survival rate than the dopamine treatment (OR 0.75; p = 0.03; [14] Dobutamine is the inotrope of choice (↑, Figure 2 ; E 34 to E 38 in eTable 1). In the dose range of 2.5 to 10 μg × kg -1 × min -1 there is a dose-effect relationship. In a multicenter cohort observation study of 1058 shock patients treated with catecholamines (15), application of dopamine was an independent risk factor for mortality, while application of dobutamine or norpinephrine was not.
In ICS refractory to catecholamine treatment, current research results support the additional use of levosimendan (loading dose 12 to 24 μg × kg -1 over 10 minutes, followed by 0.05 to 0.2 μg × kg -1 × min -1 ) more than that of phosphodiesterase III inhibitors such as enoximone or milrinone (↑, Figure 2 ; E 34 to E 38 in eTable 1) (16) . Patients with coronary heart disease with decompensated heart failure who have previously been treated with beta-blockers will have more hemodynamic benefit from a phosphodiesterase III inhibitor than from dobutamine (17) .
Skepticism about intraortic balloon counterpulsation
Both the European and the American myocardial infarction guidelines regard the use of IABP as a class I recommendation. The favorable hemodynamic effect of IABP is ascribed to an increase in diastolic coronary perfusion with a simultaneous decrease in the afterload. In ICS patients, however, the hemodynamic effects of IABP are moderate (18) : Although IABP can relieve the left ventricle-as is seen by lower BNP concentrations-the cardiac index is not significantly improved in the first few days after the onset of shock. Even more importantly, neither MODS (measured as the APACHE II score), which determines the prognosis, nor the systemic inflammation (measured as the serum IL-6 concentration) is improved by the IABP treatment (18) .
These sobering results of the randomized controlled IABP SHOCK trial (18) are confirmed by the negative results of a Cochrane analysis of six randomized studies of a total of 190 ICS patients (19) and a metaanalysis of 10 529 ICS patients from nine cohort studies (20) . The ICS patients treated with PCI (the recommended standard therapy) derived no benefit from adjunctive IABP treatment; rather, they even showed an absolute increase in mortality of 6% (ARR +6%; RRR +15%) (20) ; only when used together with systemic fibrinolysis did adjunctive IABP lead to an 18% reduction in mortality (ARR -18%; RRR -26%) (20) . It is to be hoped that the currently ongoing prospective multicenter IABP SHOCK II study (26) will elucidate whether the adjunctive use of IABP in PCItreated ICS patients can reduce mortality. Even weaker is a "may" recommendation in selected cases for the use of mechanical cardiac support systems, which, principally in animal experiments, have proved able to improve hemodynamics, reduce wall tension, and improve coronary flow reserve. However, large clinical user studies are currently under way and are expected to produce greater clarity on this point in the near future (21) .
For this reason, the German-Austrian S3 guideline gives (E 44 to E 47 in eTable 1) only a weak recommendation (↑, E 44) for the use of IABP in ICS patients treated with systemic fibrinolysis, and only "may" information for patients treated with PCI (↔, E 45).
Ventilation
Mechanical ventilation of an ICS patient ensures oxygenation and relieves the heart of the work of breathing. In contrast to the recommendation for noninvasive ventilation in patients with decompensated heart failure, in patients with ICS invasive ventilation should be preferred (↑, eFigure; E 86 in eTable 1). The reasons for this are the constant, stable ventilation conditions provided by invasive ventilation and the avoidance of psychomotor excitement that would exhaust the patient. Although hemodynamic stability is the main focus initially, the advantages of lungprotective ventilation should be made use of at the earliest possible moment (↑, E 88 in eTable 1), although the available data in this regard, especially in ICS patients, are very sparse (22) . The depth of analgesia/ sedation should be recorded three times a day using the Richmond Agitation-Sedation scale (↑, E 93 in eTable 1). Weaning, which is often difficult in ICS patients, should follow a weaning protocol (↑, E 94 in eTable 1), and before weaning starts, the following conditions should be fulfilled: hemodynamic stability, absence of myocardial ischemia, and absence or regression of inflammation or infection.
Intensive care
The initially favorable results of continuous intravenous insulin therapy with the aim of achieving normoglycemia in intensive care patients were not confirmed in later studies such as the NICE-SUGAR BOX 3 What is new in comparison to the established guidelines?
• Pressure monitoring is not enough for hemodynamic treatment after revascularisation! Additional cardiac output monitoring is mandatory.
• Dobutamine is the inotropic agent of choice; norepinephrine is the vasopressor of choice; levosimendan can be used in addition in patients with catecholaminerefractory shock.
• Even in resuscitated patients, earliest possible PCI should be considered on a case by case basis.
• Intra-aortic balloon counterpulsation (IABP) has been "down-graded."
• If ventilation is needed, it should be invasive and lung-protective. study (23) . In view of these results and of the fact that high blood glucose levels are unfavorable prognostic indicators in heart attack patients (24) At what Hb threshold value should intensive care patients receive red cell concentrates? There is controversy about this, especially in regard to intensive care patients with cardiac disease and older patients in whom increased oxygen requirement of the underperfused heart may be assumed. Given the available data, in ICS patients red cell concentrates should be given from a Hb value < 7.0 g × dL Mandatory measures in ICS patients are thrombosis prophylaxis-by means of intravenous administration of heparin-and stress ulcer prophylaxis.
Recommendations for aftercare/rehabilitation
Once the ICS patient has survived the shock, particular attention must be paid to risk stratification in the post-intensive-care phase. The current rehabilitation guidelines list both acute STEMI/NSTEMI and decompensated heart failure as class I/A indications for cardiological rehabilitation. In patients with ICS, inpatient rehabilitation lasting usually about 3 to 4 weeks should be aimed at if possible, because of the severity of the infarction event.
Discussion
The most effective treatment measure for reducing mortality among ICS patients is revascularization of the infarct vessel as early as possible (eTable 2). Despite successful revascularization, almost one in two ICS patients still dies. This is due to the sequelae of protracted shock: the severe systemic inflammatory reaction (SIRS) and the multiorgan dysfunction syndrome (MODS) (18) . Consequently, any further progress can only be achieved through effective anti-SIRS (25), anti-MODS, and general intensive care medical treatment, which hitherto have not received enough attention in ICS. Above all, comparison with the available evidence-based recommendations for the treatment of severe sepsis and septic shock shows the deficits in, for example, lung-protective ventilation and weaning, and in the standardized early hemodynamic stabilization. These aspects emphasize intensive care medicine approaches to the treatment of ICS, rather than cardiological approaches, and the present GermanAustrian guideline takes more account of them than do The infarct vessel should be revascularized as soon as possible, usually by means of PCI, in patients in the initial phase of shock within 2 hours from first contact with a physician, otherwise as early as possible Intracoronary stenting should be preferred Dobutamine should be given as an inotropic drug (↑) and norepinephrine as a vasopressor (↑). In cases of catecholamine-refractory cardiogenic shock, levosimendan or phosphodiesterase-III inhibitors should be used (↔), with levosimendan being preferred (↑)
In patients undergoing fibrinolysis treatment, IABP should be carried out adjunctively
In patients undergoing PCI, IABP may be considered, but the available evidence is unclear
In resuscitated patients whose cardiac arrest was rapidly reversed by defibrillation, earliest possible PCI should be considered on a case by case basis, since this is expected to improve the prognosis.
Mild hypothermia (32°C to 34°C) for 12 to 24 hours should be induced in comatose patients after cardiopulmonary resuscitation, both after resuscitation because of ventricular fibrillation (E 79) and because of asystole and also after cardiac arrest in hospital (E 80)
Patients with backward failure should be invasively ventilated
Invasive ventilation should be preferred to noninvasive ventilation
If ventilation is still indicated after hemodynamic stabilization, lung-protective ventilation should be given (VT ≤ 6 mL × kg 
